X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1400) 1400
Publication (109) 109
Book Review (20) 20
Book Chapter (7) 7
Data Set (2) 2
Magazine Article (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (954) 954
male (776) 776
animals (593) 593
index medicus (582) 582
pharmacology & pharmacy (438) 438
sildenafil citrate (419) 419
sulfones - pharmacokinetics (390) 390
female (366) 366
sulfones (355) 355
sulfones - pharmacology (339) 339
pharmacokinetics (300) 300
adult (277) 277
rats (273) 273
middle aged (259) 259
sildenafil (249) 249
sulfones - administration & dosage (232) 232
piperazines - pharmacokinetics (221) 221
sulfones - therapeutic use (201) 201
purines (193) 193
piperazines - therapeutic use (191) 191
administration, oral (184) 184
mice (180) 180
dose-response relationship, drug (175) 175
piperazines - pharmacology (164) 164
aged (163) 163
erectile dysfunction (163) 163
erectile dysfunction - drug therapy (162) 162
sulfones - chemistry (159) 159
sulfones - blood (138) 138
piperazines - administration & dosage (135) 135
sulfones - adverse effects (132) 132
chemistry, medicinal (127) 127
drug interactions (123) 123
piperazines - adverse effects (119) 119
treatment outcome (112) 112
phosphodiesterase inhibitors - pharmacokinetics (111) 111
rats, sprague-dawley (110) 110
area under curve (108) 108
vardenafil dihydrochloride (105) 105
phosphodiesterase inhibitors - therapeutic use (104) 104
analysis (102) 102
urology & nephrology (101) 101
chemistry, analytical (96) 96
half-life (96) 96
double-blind method (93) 93
research (92) 92
purines - pharmacokinetics (89) 89
structure-activity relationship (88) 88
toxicology (88) 88
drug therapy (87) 87
time factors (87) 87
efficacy (86) 86
biological availability (84) 84
metabolism (82) 82
tissue distribution (82) 82
sulfones - metabolism (81) 81
phosphodiesterase inhibitors - pharmacology (79) 79
purines - therapeutic use (79) 79
purines - pharmacology (78) 78
purines - administration & dosage (77) 77
safety (77) 77
chromatography, high pressure liquid (75) 75
cross-over studies (75) 75
membranes, artificial (75) 75
hypertension, pulmonary - drug therapy (72) 72
metabolites (71) 71
nonsteroidal antiinflammatory drugs (71) 71
reproducibility of results (71) 71
tadalafil (71) 71
double-blind (69) 69
impotence (67) 67
in-vitro (67) 67
adolescent (64) 64
biochemistry & molecular biology (64) 64
dogs (64) 64
oncology (64) 64
phosphodiesterase inhibitors - administration & dosage (63) 63
care and treatment (62) 62
imidazoles - pharmacokinetics (62) 62
vardenafil (62) 62
young adult (62) 62
biochemical research methods (61) 61
health aspects (61) 61
nitric-oxide (61) 61
phosphodiesterase inhibitors - adverse effects (61) 61
rats, wistar (59) 59
chromatography, high pressure liquid - methods (58) 58
rofecoxib (58) 58
biotransformation (57) 57
cancer (57) 57
disease models, animal (57) 57
pharmacology (57) 57
physiological aspects (57) 57
sulfones - chemical synthesis (57) 57
drug administration schedule (56) 56
kinetics (56) 56
expression (55) 55
identification (55) 55
imidazoles - therapeutic use (55) 55
mass spectrometry (55) 55
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1368) 1368
German (11) 11
Chinese (8) 8
Japanese (5) 5
Spanish (5) 5
French (3) 3
Russian (2) 2
Bulgarian (1) 1
Danish (1) 1
Dutch (1) 1
Hebrew (1) 1
Italian (1) 1
Norwegian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2006, Volume 33, Issue 10, pp. 917 - 924
SUMMARY • Non-steroidal anti-inflammatory drugs (NSAIDs) cause renal side-effects. In the present study, we tested the hypothesis that the extent of the renal... 
pharmacokinetics | kidney | non-steroidal anti-inflammatory drugs | cyclo-oxygenase-2 | sodium urinary excretion | cyclo‐oxygenase‐2 | non‐steroidal anti‐inflammatory drugs | Cyclo-oxygenase-2 | Pharmacokinetics | Kidney | Non-steroidal anti-inflammatory drugs | Sodium urinary excretion | GASTROINTESTINAL TOXICITY | PHYSIOLOGY | CYCLOOXYGENASE-2 | RAT | HYPERKALEMIA | PROTEIN-BINDING | MELOXICAM | INTERSPECIES DIFFERENCES | GENTAMICIN | NONSTEROIDAL ANTIINFLAMMATORY DRUGS | PHARMACOLOGY & PHARMACY | Thiazoles - blood | Area Under Curve | Thiazines - administration & dosage | Thiazines - adverse effects | Sulfones - adverse effects | Male | Thiazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Lactones - pharmacokinetics | Sodium - urine | Lactones - administration & dosage | Pyrazoles - blood | Pyrazoles - pharmacokinetics | Sulfones - blood | Placebos - administration & dosage | Pyrazoles - adverse effects | Thiazines - pharmacokinetics | Kidney - drug effects | Administration, Oral | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Thiazines - blood | Celecoxib | Lactones - adverse effects | Placebos - pharmacokinetics | Sulfones - pharmacokinetics | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Rats, Sprague-Dawley | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Potassium - urine | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Kidney, drug effects | Lactones, adverse effects | Sulfones, administration and dosage | Thiazoles, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Sodium, urine | Thiazines, blood | Anti-Inflammatory Agents, Non-Steroidal, blood | Lactones, administration and dosage | Cyclooxygenase 2 Inhibitors, adverse effects | Pyrazoles, blood | Sulfonamides, pharmacokinetics | Thiazines, pharmacokinetics | Pyrazoles, administration and dosage | Thiazoles, blood | Sulfonamides, administration and dosage | Cyclooxygenase 2 Inhibitors, administration and dosage | Lactones, pharmacokinetics | Sulfonamides, blood | Cyclooxygenase 2 Inhibitors, pharmacokinetics | Thiazines, adverse effects | Lactones, blood | Thiazoles, adverse effects | Thiazoles, pharmacokinetics | Sulfones, blood | Sulfonamides, adverse effects | Thiazines, administration and dosage | Placebos, pharmacokinetics | Sulfones, pharmacokinetics | Pyrazoles, adverse effects | Placebos, administration and dosage | Potassium, urine | Sulfones, adverse effects | Pyrazoles, pharmacokinetics
Journal Article
Journal Article
Journal Article
BMC Pharmacology and Toxicology, ISSN 2050-6511, 06/2015, Volume 16, Issue 1, pp. 18 - 18
Journal Article
Drug Metabolism and Disposition, ISSN 0090-9556, 03/2019, Volume 47, Issue 3, pp. 340 - 349
Esaxerenone (CS-3150) is a novel, nonsteroidal, selective mineralocorticoid receptor blocker. The absorption, metabolism, distribution, and excretion of... 
ANTAGONIST | CS-3150 | SPIRONOLACTONE | INJURY | RATS | PHARMACOLOGY & PHARMACY | HIGHLY POTENT | EPLERENONE | SELECTIVE ALDOSTERONE BLOCKER | PREDICTION | Pyrroles - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily G, Member 2 - metabolism | Receptors, Mineralocorticoid - metabolism | Humans | Middle Aged | Male | Metabolic Clearance Rate | Healthy Volunteers | Neoplasm Proteins - metabolism | Intestinal Absorption | Mineralocorticoid Receptor Antagonists - metabolism | Tissue Distribution | Pyrroles - administration & dosage | Adult | Caco-2 Cells | Mineralocorticoid Receptor Antagonists - administration & dosage | Pyrroles - metabolism | Administration, Oral | Sulfones - metabolism | Sulfones - pharmacokinetics | ATP Binding Cassette Transporter, Subfamily B - metabolism | Glucuronosyltransferase - metabolism | Cytochrome P-450 CYP3A - metabolism | Mineralocorticoid Receptor Antagonists - pharmacokinetics | Sulfones - administration & dosage | Renal function | Blood | Proteins | Absorption | Metabolites | Oxidation | Drug interaction | Feces | Half-life | P-Glycoprotein | Carbon 14 | Radioactivity | Glucuronosyltransferase | Urine | Excretion | UDP-glucuronosyltransferase | Drug interactions | Glycoprotein | Mass spectroscopy | Radioactive half-life | Liquid chromatography | Breast cancer | Pharmacology | Metabolism | Substrates | Isoforms | Pharmacokinetics | Mass spectrometry | Cancer
Journal Article
Journal of Ethnopharmacology, ISSN 0378-8741, 05/2016, Volume 183, pp. 9 - 17
Journal Article
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 8/2013, Volume 208, Issue 3, pp. 512 - 519
Journal Article
The Journal of Sexual Medicine, ISSN 1743-6095, 01/2013, Volume 10, Issue 1, pp. 130 - 171
Erectile dysfunction (ED) is the most frequently treated male sexual dysfunction worldwide. ED is a chronic condition that exerts a negative impact on male... 
Erectile Dysfunction | Phosphodiesterase Inhibitors | Vacuum Device Therapy | Oral Drug Treatment | Combination Therapies | Transurethral Alprostadil Therapy | Intracavernous Self-Injection Therapy | Intracavernous Self‐Injection Therapy | INTRACAVERNOUS ALPROSTADIL ALFADEX | BENIGN PROSTATIC HYPERPLASIA | PHOSPHODIESTERASE TYPE-5 INHIBITOR | URINARY-TRACT SYMPTOMS | ONCE-A-DAY | LONG-TERM SAFETY | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | VACUUM CONSTRICTION DEVICE | SELF-INJECTION THERAPY | Phosphodiesterase 5 Inhibitors - adverse effects | Humans | Middle Aged | Sulfones - adverse effects | Male | Alprostadil - therapeutic use | Erectile Dysfunction - therapy | Aged, 80 and over | Imidazoles - therapeutic use | Imidazoles - adverse effects | Risk Factors | Phosphodiesterase 5 Inhibitors - administration & dosage | Alprostadil - adverse effects | Yohimbine - adverse effects | Piperazines - therapeutic use | Sulfones - pharmacokinetics | Carbolines - administration & dosage | Piperazines - adverse effects | Sulfonamides - pharmacokinetics | Yohimbine - therapeutic use | Tadalafil | Vardenafil Dihydrochloride | Pyrimidines - pharmacokinetics | Hypogonadism - therapy | Triazines - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Triazines - pharmacokinetics | Piperazines - administration & dosage | Sulfones - therapeutic use | Age Factors | Triazines - therapeutic use | Imidazoles - administration & dosage | Imidazoles - pharmacokinetics | Phosphodiesterase 5 Inhibitors - pharmacokinetics | Alprostadil - administration & dosage | Erectile Dysfunction - drug therapy | Penile Erection - drug effects | Adult | Phosphodiesterase 5 Inhibitors - therapeutic use | Piperazines - pharmacokinetics | Drug Therapy, Combination | Carbolines - therapeutic use | Carbolines - adverse effects | Pyrimidines - administration & dosage | Erectile Dysfunction - etiology | Sulfonamides - therapeutic use | Pyrimidines - therapeutic use | Triazines - administration & dosage | Hypogonadism - complications | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Aged | Carbolines - pharmacokinetics | Hypertension | Care and treatment | Conservatism | Online health care information services | Impotence | Prosthesis | Chronic diseases | Risk factors | Testosterone | Implants, Artificial | Prostaglandins E | Diabetes | Vasoactive intestinal peptides | Special education
Journal Article